Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Company suspends enrolment to trials as coronavirus travel restrictions bite.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.
Costs will be an issue, but not today; industry and healthcare systems are working at breakneck speed to catch up with the deadly virus.
More studies are being launched into possible treatments for patients hospitalised with COVID-19, with Roche launching a Phase III, placebo-controlled trial of Actemra.
Coronavirus Update: Fujifilm Drug Shows Promise, Arrowhead Halts Trial Screening, Novartis Unveils COVID-19 Measures
Flu drug produces encouraging results in Chinese trials, while Novartis CEO Vas Narasimhan shows his public health background with package of measures.